IPA Selects Polytope™ Formulations for Pre-Clinical Studies

The pre-clinical trial will examine the safety, tolerability and efficacy of the proposed therapeutic cocktail in the SARS-CoV-2, Syrian hamster model.


ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

DuoBody technology has been successfully used in many Genmab internal or partnered investigational clinical therapies.


ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation

Thee number of issued and outstanding Common Shares being reduced from 83,809,015 to 16,761,803.


ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement

A copy of the Preliminary Shelf Prospectus can be found under the Company’s SEDAR profile at www.sedar.com and on EDGAR at www.sec.gov.


ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

The Nasdaq listing will enable the Company to gain increased liquidity and trading volume and broaden the Company’s investor base.

Items 1 to 6 of 119 total

Show per page